Smart biosurface® technology for prostate cancer detection and risk stratification through CTC enumeration and biomarker expression profiling

Résumé fourni par la source

Introduction: Prostate cancer (PCa) is one of the most prevalent cancers in men and a significant cause of cancer-related deaths. The gold standard for PCa detection and risk classification includes Prostate-Specific Antigen (PSA) testing, digital rectal examination, and tissue biopsy. However, blood-based liquid biopsy offers a non-invasive alternative for analyzing tumor cell derivatives in the bloodstream, providing molecular insights and prognostic value. Our study evaluates the use of SmartBioSurface® (SBS) Technology in patients undergoing biopsy for suspected PCa, focusing on its effectiveness in identifying clinically significant disease (Gleason Score ≥7 or Gleason Grade group ≥2 according to European Association of Urology Guidelines).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.